Abstract P255 – Table 1. Baseline characteristics of the HIV‐positive individuals vaccinated against COVID‐19 regarding the type of vaccination.
N (%)	All	Comirnaty	SpikeVax	mRNA	Vaxzevria	Janssen
All	218 (100.0)	143 (65.5)	16 (7.3)	159 (72.9)	36 (16.5)	22 (10.1)
	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)
Women	27 (12.4)	21 (14.7)	2 (12.5)	23 (14.5)	2 (5.5)	2 (9.1)
HIV VL <50 copies/mL	216 (99.1)	142 (99.3)	16 (100.0)	158 (99.4)	35 (97.2)	22 (100.0)
CD4+ <200 cells/uL	6 (2.7)	5 (3.5)	0 (0.0)	5 (3.1)	0 (0.0)	0 (0.0)
CD4+ <350 cells/uL	24 (11.0)	16 (11.2)	1 (6.2)	17 (10.7)	5 (13.9)	1 (4.5)
CD4+ <500 cells/uL	75 (34.4)	51 (35.7)	6 (37.5)	57 (35.8)	11 (30.5)	6 (27.3)
Adverse reaction after 1st vaccine dose	33 (15.1)	14 (9.8)	2 (12.5)	16 (10.1)	13 (36.1)	4 (18.2)
COVID‐19 ever	50 (22.9)	35 (24.5)	2 (12.5)	37 (23.3)	4 (11.1)	9 (40.9)
Before vaccination	18 (8.3)	12 (8.4)	2 (12.5)	14 (8.8)	0 (0.0)	2 (9.1)
After the 1st dose	4 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.8)	3 (13.6)
After the 2nd dose	11 (5.0)	9 (6.3)	0 (0.0)	9 (5.7)	2 (5.6)	0 (0.0)
After the 3rd dose	12 (5.5)	12 (8.4)	0 (0.0)	12 (7.5)	0 (0.0)	0 (0.0)